Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 baricitinib study in methotrexate-inadequate-response rheumatoid arthritis
2012-002322-73Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in rheumatoid arthritis (RA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: ACR20 response at Week 12. Started Nov 2012; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-002322-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002322-73.